AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. In 2013, AbbVie employs approximately 21,000 people worldwide and markets medicines in more than 170 countries. For further information on the company and its people, portfolio and commitments, please visit www.abbvie.com. Follow @abbvie on Twitter or view careers on our Facebook or LinkedIn page.
i Clinical Study Protocol M11-352. AbbVie. Date Accessed: April 1, 2013.
ii European Renal Association - European Dialysis and Transplantation Association (ERA-EDTA). Oral Presentation 034932, "The Selective Type A Endothelin Antagonist Atrasentan Reduces Residual Albuminuria in Patients with Type 2 Diabetes and Nephropathy."iii Temporal Trends in the Prevalence of Diabetic Kidney Disease in the United States. The Journal of the American Medical Association. Date Accessed: October 28, 2011. iv Diabetic Nephropathy. Cleveland Clinic. Available at: http://www.clevelandclinicmeded.com/medicalpubs/diseasemanagement/nephrology/diabetic-nephropathy/. Date Accessed: April 22, 2013. v IDF Diabetes Atlas: Global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Atlas. Date Accessed: May 2, 2013. vi Medical Care Costs Associated With Progression of Diabetic Nephropathy. Diabetes Care. Date Accessed: May 2, 2013. vii Kidney Disease of Diabetes. National Kidney and Urologic Diseases Information Clearinghouse (NKUDIC). Accessed: May 2, 2013 SOURCE AbbVie
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV